Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

Key Inclusion Criteria: * Diagnosis of metastatic lung cancer, with histologic confirmation of the primary NSCLC histology and with at least one lesion amenable for intra-tumoral injection of MV-NIS. * Patient meets the FDA-approved indication for Atezolizumab treatment in NSCLC. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. * Ability to provide informed consent. * Adequate hematological, liver and kidney function. * Must be willing to implement contraception throughout study and for the 8 weeks following last study drug administration. Key Exclusion Criteria: * Any of the following prior therapy: Chemotherapy ≤ 3 weeks prior to registration. Biologic therapy ≤ 4 weeks prior to registration. Radiation therapy ≤ 3 weeks prior to registration * Other concurrent investigational therapy (utilized for a non-FDA-approved indication and in the context of a research investigation). * Pregnant women. * Nursing women. * Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of study drug treatment. * Allergy to measles vaccine or history of severe reaction to prior measles vaccination. * History of organ transplantation.